Peptide LibraryPralmorelin (GHRP-2) dosage in published studies and labels
These are the doses used for Pralmorelin (GHRP-2) in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.
Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.
Last checked against primary sources:
Studied regimens and sources
GHRP-2, developed as pralmorelin, has established human dosing for one narrow purpose: a 100 mcg intravenous bolus used as a growth hormone stimulation test. It is a recognised diagnostic alternative to the insulin tolerance test in Japan. There is no FDA-labelled product and no trial establishing a repeated-dosing regimen for growth hormone or body-composition use.
| Human dosing established | Yes |
|---|---|
| Studied dose range | 100 mcg intravenous bolus (diagnostic test dose) |
| Route | Intravenous |
| Frequency | Single bolus as a stimulation test |
| Duration studied | Acute; sampling over 60 minutes |
| Evidence level | Limited Human Evidence |
| Last reviewed | 2026-09-05 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Vasopressin secretion study in healthy men (2010)Clinical trial · Human endocrine physiology study | 10 healthy men, fasting and non-fasting | 100 mcg | Intravenous bolus | Single dose | Sampling at 15, 30, 45 and 60 minutes | ACTH, GH, FSH, LH, prolactin, TSH and vasopressin responses | GH-releasing peptide-2 does not stimulate arginine vasopressin secretion in healthy men. Endocr J. 2010. |
| Diagnostic comparison against the insulin tolerance test (2013)Clinical trial · Diagnostic accuracy study | 71 pre-operative adults with pituitary tumours, aged 18-65 | Per the standard GHRP-2 test protocol | Intravenous | Single stimulation test | Acute | Diagnosis of adult growth hormone deficiency versus the insulin tolerance test | The arginine and GHRP-2 tests as alternatives to the insulin tolerance test for the diagnosis of adult GH deficiency in Japanese patients. Endocr J. 2013. |
| Development profile - pralmorelinResearch-reported · Drug development profile | Development-stage summary | No maintenance regimen reported | Various | — | — | Development status of GHRP-2 / KP-102 | Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN. Drugs R D. 2004. |
Where sources disagree
- The 100 mcg dose is a single diagnostic stimulus given once in a clinic to provoke a measurable growth hormone response. It is not a treatment dose, and nothing about it validates repeated administration. GHRP-2 is nonetheless sold with protocols of 100-300 mcg two or three times daily.
- GHRP-2 raises ACTH, cortisol and prolactin as well as growth hormone. That is documented in the same human studies used to support its growth hormone effect.
- Approval as a diagnostic agent in Japan does not create a US approved dose, and DailyMed lists no product under pralmorelin or GHRP-2.